Statins as potential disease-modifying therapy of Parkinson's disease: a systematic review and meta-analysis with trial sequential analysis

期刊论文
发表日期：

2024年12月30日

查看全文

Ocílio Ribeiro Gonçalves,
Arquimedes Barros Nascimento,
Victor Gonçalves Soares,
David Abraham,
Gabriel de Almeida Monteiro,
João Luís Reis Freitas,
Jonatas Paulino da Cunha Monteiro Ribeiro,
Bianca Leal Ribeiro,
João Victor Araújo de Oliveira,
Marco Antonnio Rocha dos Santos,
João Paulo Mota Telles,
Flávio Sekeff-Sallem,
Kelson James Almeida

摘要

Background

Recent evidence indicates that statins have anti-inflammatory and antioxidant effects, leading to several investigations of whether statins have a neuroprotective effect and may benefit patients with Parkinson’s disease (PD). However, the potential mechanisms of this class of medications as modifiers of the course of PD in already diagnosed patients is still unclear.

Objectives

To assess the effectiveness of statins as modifiers of established PD.

Methods

Two investigators systematically searched for randomized clinical trials and observational studies comparing PD patients treated with statins versus those treated without statins. The search was conducted in PubMed, Embase, Cochrane, and Web of Science. The outcome of interest was the change in the MDS-UPDRS III (Movement Disorder society—Unified Parkinson's Disease Rating Scale Part III) and UPDRS III scores from baseline. Statistical analysis was performed using R Studio 4.3.2.

Results

Four studies, totaling 472 patients, were included. The standardized mean difference for the MDS-UPDRS Part III and UPDRS Part III scales between statin and non-statin groups was − 0.13 (95% CI − 0.44 to 0.17; p = 0.39; I² = 58%), and there was no statistical significant difference regarding this outcome.

Conclusion

There was no statistical significance for the potential clinical benefit of statins as modifiers of the disease course in PD patients.